TABLE 1.

Origins and antifungal susceptibilities of atypical isolates

Patient	Isolate	Yra	Prior therapyb	Site of isolationc	MIC/MFCd (μg/ml)			MEC of CAS (μg/ml)
					ITZ	VRZ	AMB
1	W1	1995	FLU, AMB	Lung	0.5/1	2/4	2/4	16
	W2	1995	FLU, AMB	Kidney	1/2	2/4	1/2	4
2	W3	1998	FLU	Mouth	1/2	2/4	2/2	16
	W4	1998	FLU	Lung	1/2	2/4	1/2	>32
3	W5	1999	FLU	Lung	1/2	2/2	2/4	16
4	W6	2000	AMB, VRZ	Lung	1/2	2/4	1/4	32
	W7	2000	AMB, VRZ	Mouth	1/2	2/4	2/4	32

^aYear during which isolates were recovered from the indicated site.

^bAntifungal therapy prior to day of infection.

^cIsolates recovered from either bronchoalveolar lavage or lung biopsy specimens are indicated as “lung.” Kidney isolates were recovered at autopsy.

^dMICs shown were determined by the NCCLS method, as described in Materials and Methods.